1.陕西中医药大学第二附属医院脑病科(陕西 咸阳 712000)
2.西北大学生命科学院(陕西 西安 710000)
李卫萍,女,主治医师,主要从事痴呆的基础研究与临床工作
申艳方,主治医师;E-mail:747682799@qq.com
扫 描 看 全 文
李卫萍,申艳方,杜菊梅,等.芪蛭通络胶囊治疗气虚血瘀型血管性认知障碍的随机、双盲、安慰剂对照临床研究[J].上海中医药杂志,2022,56(7):59-63.
LI Weiping,SHEN Yanfang,DU Jumei,et al.Clinical study on treatment of vascular cognitive impairment of qi deficiency and blood stasis syndrome with Qizhi Tongluo Capsule:a randomized, double⁃blind, and placebo⁃controlled trial[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(7):59-63.
李卫萍,申艳方,杜菊梅,等.芪蛭通络胶囊治疗气虚血瘀型血管性认知障碍的随机、双盲、安慰剂对照临床研究[J].上海中医药杂志,2022,56(7):59-63. DOI: 10.16305/j.1007-1334.2022.2103085.
LI Weiping,SHEN Yanfang,DU Jumei,et al.Clinical study on treatment of vascular cognitive impairment of qi deficiency and blood stasis syndrome with Qizhi Tongluo Capsule:a randomized, double⁃blind, and placebo⁃controlled trial[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(7):59-63. DOI: 10.16305/j.1007-1334.2022.2103085.
目的,2,观察芪蛭通络胶囊治疗气虚血瘀型血管性认知障碍的临床疗效。,方法,2,将90例气虚血瘀型血管性认知障碍患者随机分为治疗组(60例)和对照组(30例)。两组均予基础治疗,治疗组加用芪蛭通络胶囊,对照组加用芪蛭通络胶囊安慰剂,疗程均为24周。观察临床疗效,比较中医证候积分及简易精神状态检查(MMSE)、画钟测验(CDT)、霍普金斯词语学习测验(HVLT)评分的变化情况,并进行安全性评价。,结果,2,①试验过程中,治疗组脱落3例,对照组脱落2例,最终完成试验者85例,其中治疗组57例、对照组28例。②治疗组临床总有效率为94.74%,对照组临床总有效率为53.57%;两组临床疗效比较,治疗组优于对照组(,P,<,0.01)。③治疗前后组内比较,两组气虚证候量表、血瘀证候量表积分减少(,P,<,0.01);组间治疗后比较,治疗组气虚证候量表、血瘀证候量表积分少于对照组(,P,<,0.01)。④治疗前后组内比较,治疗组MMSE、CDT、HVLT评分升高(,P,<,0.05);组间治疗后比较,MMSE、CDT、HVLT评分差异有统计学意义(,P,<,0.05)。⑤两组在试验期间均未出现严重的不良反应。,结论,2,芪蛭通络胶囊治疗气虚血瘀型血管性认知障碍疗效满意,能很好地改善患者的认知功能障碍及中医证候,且安全性良好。
Objective,2,To observe the clinical efficacy of Qizhi Tongluo Capsule in treating vascular cognitive impairment (VCI) of qi deficiency and blood stasis syndrome.,Methods,2,Ninety patients with VCI of qi deficiency and blood stasis syndrome were randomly divided into a treatment group (,n,=60) and a control group (,n,=30), and both groups were given basic treatment. The treatment group was additionally administered with Qizhi Tongluo Capsule and the control group was given Qizhi Tongluo Capsule mimics. The treatment course was 24 weeks. The clinical efficacy was observed, and the changes in the TCM syndrome scores as well as the scores of the Mini-mental State Examination (MMSE), the Clock Drawing Test (CDT) and the Hopkins Word Learning Test (HVLT) were compared. The safety evaluation was performed.,Results,2,①During the trial, there were 3 drop-out cases in the treatment group and 2 drop-out cases in the control group, and 85 cases finally completed the trial, including 57 cases in the treatment group and 28 cases in the control group. ②The total clinical effective rate of the treatment group was 94.74%, and that of the control group was 53.57%; the clinical efficacy of the treatment group was better than that of the control group (,P,<,0.01). ③The scores of qi deficiency syndrome scale and blood stasis syndrome scale decreased in both groups after treatment (,P,<,0.01); the scores of qi deficiency syndrome scale and blood stasis syndrome scale in the treatment group were lower than those in the control group (,P,<,0.01). ④The MMSE, CDT, and HVLT scores increased in the treatment group after treatment (,P,<,0.05); the differences in MMSE, CDT, and HVLT scores between the two groups were statistically significant after treatment (,P,<,0.05). ⑤No serious adverse reaction was observed in both groups during the trial.,Conclusion,2,Qizhi Tongluo Capsule has achieved satisfactory results in treating vascular cognitive impairment of qi deficiency and blood stasis syndrome, and it can significantly improve the cognitive dysfunction and TCM syndromes of patients with good safety.
血管性认知障碍痴呆气虚血瘀证芪蛭通络胶囊补阳还五汤临床试验
vascular cognitive impairmentdementiaqi deficiency and blood stasis syndromeQizhi Tongluo CapsuleBuyang Huanwu Decoctionclinical trial
DIEHL J , KURZ A . Update on vascular dementias[J]. J Geriatr Psychiatry Neurol, 2016, 29(5): 281-301.
SANTOS M A O, BEZERRA L S, CORREIA C D C, et al. Neuropsychiatric symptoms in vascular dementia: epidemiologic and clinical aspects[J]. Dement Neuropsychol, 2018, 12(1): 40-44.
MORTON R E, ST JOHN P D, TYAS S J. Migraine and the risk of allcause dementia, Alzheimer’s disease, and vascular dementia: A prospective cohort study in community-dwelling older adults[J]. Int J Geriatric Psychiatry, 2019, 34(11): 1667-1676.
O’BRIEN J T, THOMAS A. Vascular dementia[J]. Lancet, 2015, 386(10004): 1698-1706.
SUN M K. Potential therapeutics for vascular cognitive impairment and dementia[J]. Curr Neuropharmacol, 2017, 15(7): 1036-1044.
单永琳. 芪参还五胶囊促进早期血管性痴呆患者智能缺损程度、脂代谢紊乱恢复临床研究[J]. 亚太传统医药,2017, 13(4): 152-154.
赵欢,杨东东,郭强,等. 基于“精-血-髓一体论”观察当归补血汤治疗血管性痴呆临床研究[J]. 陕西中医,2016, 37(10): 1314-1315,1435.
WENTZEL C, ROCKWOOD K, MACKNIGHT C, et al. Progression of impairment in patients with vascular cognitive impairment without dementia[J]. Neurology, 2001, 57(4): 714-716.
JIANG B, DING C, YAO G, et al. Polysomnographic abnormalities in patients with vascular cognitive impairment-no dementia[J]. Sleep Med, 2013, 14(11): 1071-1075.
时晶,魏明清,马福云,等. 血管性认知损害的中医证候特征[J]. 中医杂志,2012, 53(6): 503-506.
ROMÁN G C, WILKINSON D G, DOODY R S, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials[J]. Dement Geriatr Cogn Disord, 2005, 20(6): 338-344..
国家药品监督管理局. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002: 99-104.
中国老年保健协会老年痴呆及相关疾病专业委员会. 中国血管性轻度认知损害诊断指南[J]. 中华内科杂志,2016, 55(3): 249-256.
GORELICK P B, SCUTERI A, BLACK S E, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association[J]. Stroke, 2011, 42(9): 2672-2713.
BARKER W W, LUIS C A, KASHUBA A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank[J]. Alzheimer Dis Assoc Disord, 2002, 16(4): 203-212.
SCHNEIDER J A, ARVANITAKIS Z, BANG W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons[J]. Neurology, 2007, 69(24): 2197-2204.
ESIRI M M, MATTHEWS F, BRAYNE C, et al. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales[J]. Lancet, 2001, 357(9251): 169-175.
MOORHOUSE P, ROCKWOOD K. Vascular cognitive impairment: current concepts and clinical developments[J]. Lancet Neurol, 2008, 7(3): 246-255.
KIM H J, JANG B K, PARK J H, et al. A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine induced mouse model[J/OL]. Eur J Med Chem, 2020,185: 111777[2021-03-01]. https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(19)30929-8https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(19)30929-8.
FAYEZ A M, ELNOBY A S, BAHNASAWY N H, et al. Neuroprotective effects of zafirlukast, piracetam and their combination on L-Methionine-induced vascular dementia in rats[J]. Fundam Clin Pharmacol, 2019, 33(6): 634-648.
LEYS D, HÉNON H, MACKOWIAK-CORDOLIANI M A, et al. Poststroke dementia[J]. Lancet Neurol, 2005, 4(11): 752-759.
邵亚兰,郑露茜,杨树龙. 血管性痴呆的中医药治疗新进展[J]. 中国医药导报,2019, 16(21): 39-42.
ZHI X, JOAS E, WAERN M, et al. Prevalence of cardiovascular disorders and risk factors in two 75-year-old birth cohorts examined in 1976-1977 and 2005-2006[J]. Aging Clin Exp Res, 2013, 25(4): 377-383.
陈昱彤,喻嵘,谭艳,等. 血管性认知障碍的中医证型、证素分布及用药规律[J]. 湖南中医药大学学报,2021, 41(6): 869-874.
凌佳,张宗奇,李清华,等. 治疗血管性认知障碍的中药有效成分研究进展[J]. 临床内科杂志,2021, 38(11): 734-737.
王健康,李静. 川蛭通络胶囊联合瑞舒伐他汀对血脂水平正常急性脑梗死患者神经功能的影响[J]. 中国社区医师,2021, 37(3): 127-128.
刘立伟. 芪蛭通络胶囊合杞菊地黄丸治疗非增殖期糖尿病视网膜病变临床观察[J]. 光明中医,2019, 34(14): 2152-2154.
张文智. 基于血清药化研究芪蛭通络胶囊通络及开窍药的药效物质基础[D]. 太原:山西省中医药研究院,2020.
兰鹏,苏锦勋,潘凤仙. 芪蛭通络胶囊治疗血管性轻度认知障碍的疗效观察[J]. 辽宁中医杂志,2016, 43(4): 752-753.
吴鹏,邢俊娥,邢远,等. 藿苓益智方联合芪蛭通络胶囊对帕金森病痴呆患者临床疗效的研究[J]. 辽宁中医杂志,2020, 47(8): 103-106.
张婷婷,滕尧,陆雪健,等. 芪蛭胶囊对缺血性中风大鼠PKC-MARCKS信号通路相关蛋白表达的影响[J]. 中华中医药杂志,2021, 36(1): 402-406.
孙芮芮. 芪蛭通络胶囊改善东莨菪碱致小鼠记忆障碍的研究[D]. 太原:山西中医药大学,2020.
0
浏览量
265
下载量
0
CSCD
1
CNKI被引量
关联资源
相关文章
相关作者
相关机构